Drug intelligence / Profile preview

boserolimab + pembrolizumab

Development stage: Unknown
Lead developer: Merck
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

This combination involves **boserolimab (MK-5890)**, an investigational drug, and **pembrolizumab (MK-3475, Keytruda)**, a PD-1 inhibitor. Pembrolizumab works by blocking the PD-1 receptor on T cells, enhancing the immune response against cancer cells. Boserolimab's specific mechanism is not detailed in the available data, but it is being studied in combination with pembrolizumab for advanced solid tumors, including non-small cell lung cancer and triple-negative breast cancer.

Brand names: Keytruda
Other names: pembrolizumab plus boserolimabpembrolizumab and boserolimab

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on boserolimab + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on boserolimab + pembrolizumab.

Explore the full profile